Knowledge of indeterminate colitis continues to evolve as the concept was first introduced by Dr Ashley Price in 1978. 1 While most of inflammatory bowel disease cases are further classified into either ulcerative colitis or Crohns disease, 5-10% of inflammatory bowel disease patients bear equivocal features, falling into the category of indeterminate colitis. [2] [3] [4] According to the World Congress of Gastroenterology Montreal Recommendations, 5 the diagnosis of indeterminate inflammatory bowel disease should be made only after colectomy, in cases where definitive features of Crohns disease and ulcerative colitis are absent. Although the nature of disease of most indeterminate inflammatory bowel disease patients becomes evident over time, a portion of patients remain indeterminate. As Crohns disease is an important contradiction for ileal pouch-anal anastomosis for continence restoration after colectomy, more precise classification of indeterminate inflammatory bowel disease is a highly sought after clinical goal.
Some serological markers, such as anti-Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic antibodies, have been applied to attempt improved classification of indeterminate inflammatory bowel disease. 6 However, these markers have low specificity and sensitivity as born out by longterm clinical outcomes. Better markers are greatly needed.
MicroRNAs, are small noncoding RNAs, that have an important role in cellular processes of differentiation and apoptosis. 7 Furthermore, microRNAs have been shown to regulate chronic inflammation in autoimmune disease. 8, 9 microRNAs were reported to be differentially expressed in colonic mucosal tissue of Crohns disease patients in a microRNA microarray study, compared with the normal noninflammatory bowel disease controls or ulcerative colitis patients. 10, 11 This study now examines the role of five differentially expressed microRNA between ulcerative colitis and Crohns disease for distinguishing classically diagnosed indeterminate inflammatory bowel disease.
Materials and methods

Human Colonic Tissues
Fresh frozen colonic mucosa was sampled from colectomies of the following patient groups: 16 indeterminate inflammatory bowel disease, 14 Crohns disease, 12 ulcerative colitis, and a normal control group of 11 patients with diverticular disease. Institutional review board approval was strictly maintained. The biopsy samples were obtained from the distal-most involved part of the colectomy specimens, snap frozen in liquid nitrogen, and held at À 801C. Frozen sections were performed to confirm the nondysplastic histology and to evaluate the degree of the inflammation in each sample. Patients had a medical diagnosis of ulcerative colitis, Crohns disease, indeterminate inflammatory bowel disease, or diverticular disease and the pathologic colectomy diagnosis was confirmed in each. The slides were reviewed by two gastrointestinal pathologists (JL and MPB).
The demographic features were summarized in Table 1 . The mean time from initial presentation of inflammatory bowel disease to colectomy in indeterminate inflammatory bowel disease group was 9 years 3 months, ranging from 3 months to 27 years. The mean postcolectomy follow-up time of indeterminate inflammatory bowel disease patients was 4 years 5 months, with a range from 1 year 1 month to 7 years 9 months. Seven indeterminate colitis patients had pouch constructed with a follow-up period ranging from 21 months to 93 months (Table 3 ). Most of them had no pouch complications during follow-up, except one patient whose pouch ultimately failed and was resected 1 year and 9 months later due to recurrent inflammatory bowel disease (patient 13).
Diagnostic Criteria for Ulcerative Colitis, Crohns Disease, and Indeterminate Inflammatory Bowel Disease Briefly, the cardinal pathologic features of ulcerative colitis are those of a chronic colitis with superficial disease that is usually diffuse but occasionally patchy. Ulcerative colitis may develop fulminant deep ulcers but it lacks the transmural discrete lymphoid aggregates remote from ulcers and noncrypt rupture granulomas typical of Crohns disease. Ileal involvement as backwash ileitis in direct continuity with pancolonic ulcerative colitis was also permitted for the diagnosis of ulcerative colitis, as validated by long-term pouch outcome studies, 12 but it lacked the diagnostic mural features of Crohns disease (discrete lymphoid aggregates remote from ulcers and/or strictures, adhesions or fistula). The diagnosis of Crohns disease required chronic colitis with transmural discrete lymphoid aggregates remote from ulcers, with or without noncrypt rupture granulomas, strictures, adhesions, or fistula. Diverted rectal specimens were not used to differentiate ulcerative colitis and Crohns disease, due to their well reported tendency to nonspecifically mimic the transmural features of Crohns disease. [13] [14] [15] [16] 
Total Small RNA Extraction
The frozen tissues were dissolved in 700 ml of Qiazol reagent (Qiagen, USA) and total small RNA was extracted using miRNeasy mini isolation kit (Qiagen, USA) according to the manufacturers' instructions. The RNA samples were stored at À 801C.
Quantitative Reverse-Transcription-PCR
The microRNA enrichment from the study and control groups was performed using TaqMan s microRNA Reverse Transcription Kit (Applied Biosystems by Life Technologies, USA) and TaqMan s Universal PCR Master Mix system (Applied Biosystems by Life Technologies, USA). Briefly, 50 ng of small RNA was converted to complementary DNA. Commercially available microRNA primers were used (Applied Biosystems by Life Technologies, USA). The expression of each microRNA in the sampled colonic mucosa was calculated as a value relative to U6B, a ubiquitously expressed small nuclear RNA that has been widely accepted as a stably expressed internal control. The levels of each target microRNA in the study groups were normalized to the mean value of the control group. Each sample was performed in duplicate.
Statistical Analysis
Experimental results were expressed as mean values. Univariate analysis of variance was performed to investigate differences in microRNA expression between the study and control groups. The SAS Proc General Linear Model was used to fit analysis of variance models because the sample sizes of the groups compared were different (ie, unbalanced data). If there was an overall statistically significant difference, post hoc pairwise comparisons would be performed to test which specific pairs were significant. A P value of o0.05 was considered significant. Discriminant analysis was conducted to evaluate the capacity of five markers, as a whole, to differentiate and classify the diseases of interest. All analyses were performed with SAS (version 9.2, SAS Institute Inc., Cary, NC, USA).
Results
MicroRNAs Differentially Expressed in Colonic Tissue Between Ulcerative Colitis and Crohns Disease Patients
In this study, we first confirmed the expression pattern of five microRNAs, miR-19b, miR-23b, miR106a, miR-191, and miR-629, in the colonic mucosal tissue from patients with ulcerative colitis, Crohns disease and the control group. The expression of each microRNA was normalized to its internal control, U6B, and then each value in the study groups was standardized to the mean value of the control group ( Table 2) . Analysis of variance showed significant difference in expression of miR-19b, miR-23b, miR106a, and miR-629 between the Crohns disease group and control group (Po0.05, data not shown).
No differences were observed between the ulcerative colitis and control groups in all five microRNAs (P40.05, data not shown), which is consistent with the finding in the previous study. 11 Finally, three microRNAs, miR-19b, miR-106a, and miR-629, were statistically differentially expressed in colonic tissue between ulcerative colitis and Crohns disease groups, respectively (Po0.05). The differential expression of the five tested microRNAs between ulcerative colitis and Crohns disease groups makes them suitable markers to characterize the features of indeterminate inflammatory bowel disease. As shown in Table 2 , the expression of all five microRNAs was significantly different between indeterminate inflammatory bowel disease and Crohns disease groups (Po0.05), respectively. Interestingly, there was no difference between indeterminate inflammatory bowel disease and ulcerative colitis groups in any of these microRNAs (P40.05, data not shown). Thus, the expression level of the five selected microRNAs in indeterminate inflammatory bowel disease, as a whole, is similar to that of ulcerative colitis, not Crohns disease.
Discriminant Analysis of Five MicroRNAs to Distinguish Crohns Disease-Like Pattern From Ulcerative Colitis-Like Expression Pattern
Discriminant analysis was performed to study whether, as a whole, the five microRNA markers had a good capacity in distinguishing diseases of interest. Nine of 14 Crohns disease patients had Crohns disease-like microRNA expression pattern; the prediction accuracy was 64.3%. All ulcerative colitis patients had ulcerative colitis-like microRNA expression pattern with 100% prediction accuracy.
Five Panel MicroRNA Expression Pattern in Indeterminate Inflammatory Bowel Disease
Among the 16 indeterminate inflammatory bowel disease patients, fifteen showed ulcerative colitislike and one Crohns disease-like microRNA expression pattern (patient 10 in Table 3 without pouch construction.
The Degree of Inflammation of the Frozen Tissue
The involvement of inflammation of each frozen sample was evaluated based on the degree of inflammation and was classified into no inflammation, cryptitis, crypt abscess, numerous crypt abscesses (43/high-power field) and ulceration. As shown in Table 4 , most of the controls showed no active inflammation; however, most of the specimens of the study groups, including Crohns disease, ulcerative colitis and indeterminate colitis demonstrated variable degrees of inflammation, ranging from cryptitis, crypt abscess, to ulceration. The expression levels of five miRNAs were not associated with the degree of inflammation in the current study (data not shown).
Discussion
Idiopathic inflammatory bowel disease of indeterminate type represents a heterogenous group of patients that bear equivocal features of both ulcerative colitis and Crohns disease. These patients manifest a spectrum of disease with classical ulcerative colitis and classical Crohns disease at either end. Knowledge of indeterminate inflammatory bowel disease patients accumulates from clinical observation and long-term follow-up that can delay or even prevent definitive pouch surgery to restore continence. Thus, the most pertinent question regarding the surgical decisions in indeterminate inflammatory bowel disease patients is whether to provide an ileal pouch-anal anastomosis for continence restoration. Ileal pouch-anal anastomosis is most clearly indicated for ulcerative colitis patients, but remains [17] [18] [19] Based on long-term clinical outcome studies, it appears that most indeterminate inflammatory bowel disease patients will ultimately behave clinically like ulcerative colitis patients. 20, 21 Accordingly, indeterminate inflammatory bowel disease patients are often deemed appropriate candidates for ileal pouch-anal anastomosis, although they have an increased complication rate compared with ulcerative colitis. 17, 22 Ultimately, the best means of selecting ileal pouch-anal anastomosis candidates within the indeterminate inflammatory bowel disease population remains an important clinical question. To further advance this clinical need, a simple strategy by sorting microRNA expression patterns of indeterminate inflammatory bowel disease into Crohns disease-like versus ulcerative colitis-like would be practical. Based on this rationale, we applied discriminant analysis of microRNA expression of a panel of five markers in each indeterminate inflammatory bowel disease patient studied. The underlying molecular mechanism governing the diagnoses of ulcerative colitis, Crohns disease and indeterminate inflammatory bowel disease remain a mystery. In this paper, we explored the expression pattern of microRNAs in indeterminate inflammatory bowel disease in comparison to the other two major groups of inflammatory bowel disease, namely ulcerative colitis and Crohns disease. Our data provide molecular evidence, for the first time to our knowledge, that microRNA expression patterns in indeterminate inflammatory bowel disease, as a whole, are similar to those of ulcerative colitis and not Crohns disease. Clinically, most indeterminate inflammatory bowel disease patients behave similarly to those of ulcerative colitis patients in longterm follow-up, which is supported by the parallel microRNA background in both, as demonstrated in this paper. The advantage of microRNA analysis is its immediate determination at the time of colectomy without the need for long-term clinical outcome validation of ulcerative colitis-like biology.
A two-tier system of classifying indeterminate inflammatory bowel disease into Crohns diseaselike versus ulcerative colitis-like microRNA expression pattern using discriminant analysis, although simple, could be of practical value from the clinical point of view. In this study, most of the indeterminate inflammatory bowel disease patients had no pouch complications during follow-up, except one patient whose pouch ultimately failed because of the severe pouchitis and was resected 1 year and 9 months postcolectomy (patient 13). Of course, Crohns disease is only one of many reasons that pouches fail. Owing to the small size of the current study, further validation of microRNA expression patterns in large series with the long-term pouch and overall clinical outcomes will be essential. Ideally, we want to establish a discriminant analysis model to distinguish each individual indeterminate inflammatory bowel disease patients by combining both clinicopathologic and microRNA data to aid treatment decisions as whether they should or should not receive pouch surgery. The added molecular evidence could therefore provide further assurance that indeterminate inflammatory bowel disease patients have been correctly selected for pouch restorative surgery.
All five selected miRNAs show differential expression pattern between the Crohns disease and the ulcerative colitis groups, which makes them useful markers to distinguish the two major subclass of inflammatory bowel disease. No differences were observed between the ulcerative colitis and control groups in all five microRNAs, which is consistent with the finding in the previous study. 11 All five markers are upregulated in Crohns disease group in the current study; however, two of them, miR-19b and miR-629, showed decreased expression in Wu's study. 11 These two miRNAs demonstrate good differential expression with solid controls in our study; however, we don't know how to explain the difference compared with the prior study. May be it is confounded by the different sample cohorts, the different location of the colon from where the frozen tissue was sampled, or the different degree of inflammation of the frozen tissue. As shown in our study, there is no association between the expression levels of miRNAs and the degree of inflammation.
Among the five selected microRNAs studied, aberrant expression of miR-106a is known to be associated with a variety of diseases, including inflammatory diseases in the other organ system and colon cancer. [23] [24] [25] [26] miR-106a posttranscriptionally regulates the expression of interleukine-10 (IL-10), which is a key modulator of the immune system. On the other hand, miR-106a expression is regulated by tumor necrosis factor alpha and lipopolysaccharide. 24 The role of miR-106a seems to be involved in finely tuning the critical expression of IL-10 in response to particular external stimuli. Thus, miR106a and its regulators comprise a complex regulatory network. The overexpression of microRNAs, including miR-106a, and their subsequent downstream target protein expression in Crohns disease, not in ulcerative colitis and most indeterminate inflammatory bowel disease, may be associated with the particular clinical presentation of Crohns disease and its related clinical outcome. As such, microRNAs are potential molecular markers to classify the subtype of inflammatory bowel disease, especially at an early stage when the disease has not clarified itself. In summary, microRNA expression patterns for the five-marker panel used in this study provide molecular evidence that most indeterminate inflammatory bowel disease cases are probably ulcerative colitis. This parallels the established clinical findings, but has the considerable advantage of being testable at the time of colectomy for improved pouch surgery selection. Our study did find one indeterminate patient with a Crohns disease-like micro-RNA expression pattern, and the utility of this type of analysis will be to better define such patients for pouch selection. Long-term clinical validation remains a necessity, but these microRNA results are promising for improving the classification of indeterminate inflammatory bowel disease. MicroRNA may be a potential diagnostic and prognostic marker to better delineate indeterminate inflammatory bowel disease patients, and prevent possible Crohns-related pouch complications.
